Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Syntiron, a biotech company located in St Paul, Minnesota, has received a US government grant under the Qualifying Therapeutic Discovery Project (QTDP) Program, in support of its Bacterial Vaccine and Therapeutic Platform Technology.
Subscribe to our email newsletter
The $244,479 grant includes the development of vaccines to prevent infections by Yersinia, Salmonella and Staphylococcus bacteria.
The QTDP program, included as part of the Patient Protection and Affordable Care Act of 2010, is a tax credit intended to support biomedical research in the US.
Syntiron CEO Joe Shaw said that the funds would be utilised to advance the development of Syntiron’s platform of vaccine technology.
Syntiron holds the exclusive license to the human applications of the Epitopix patented SRP technology which Epitopix already markets for veterinary applications.